EyePoint Pharmaceuticals. has been granted a patent for compounds that activate Tie-2 and inhibit HPTP-beta, offering potential therapies for eye conditions such as intraocular pressure, ocular hypertension, and glaucoma. The patent also includes a method to increase the area of Schlemm’s canal using a Tie-2 activator. GlobalData’s report on EyePoint Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on EyePoint Pharmaceuticals, NSAID cancer drugs was a key innovation area identified from patents. EyePoint Pharmaceuticals's grant share as of July 2024 was 42%. Grant share is based on the ratio of number of grants to total number of patents.
Therapeutic compounds for treating eye conditions like glaucoma
The granted patent US12064420B2 outlines a method aimed at increasing the area of Schlemm's canal in the eye of a subject requiring such intervention. Central to this method is the administration of a therapeutically effective amount of a Tie-2 activator, which is defined by a specific chemical formula. The claims specify that this administration can lead to an increase in the area of Schlemm's canal by at least 12% compared to scenarios where no such activator is administered. Various delivery methods for the Tie-2 activator are described, including unit dosage forms, sustained release formulations, solid hydrophobic polymers, and microparticles. The administration routes can be topical, subcutaneous, or intravitreal, allowing for flexibility in treatment approaches.
Additionally, the patent details the mechanisms by which the Tie-2 activator functions, including its ability to bind to and inhibit HPTPß within the Schlemm's canal. The claims emphasize that the activation of Tie-2 occurs upon administration of the activator, which is crucial for achieving the desired increase in canal area. The increase is quantitatively assessed by comparing the area of the Schlemm's canal at baseline to the area post-administration. This patent presents a novel therapeutic strategy for potentially addressing conditions related to the eye, particularly those affecting intraocular pressure and fluid drainage.
To know more about GlobalData’s detailed insights on EyePoint Pharmaceuticals, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
